News Daily News New Performance and Quality Metrics for STEMI and NSTEMI Care Michael O'Riordan September 21, 2017
News Conference News ESC 2017 Inclisiran Offers Sustained LDL-Lowering Through 1 Year: ORION-1 Michael O'Riordan September 05, 2017
News Conference News ESC 2017 Women at High Cardiovascular Risk Unlikely to Get to Low LDL Targets Michael O'Riordan August 30, 2017
News Conference News ESC 2017 Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed Michael O'Riordan August 29, 2017
News Conference News ESC 2017 Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab Michael O'Riordan August 28, 2017
News Conference News ESC 2017 ESC Updates Guidelines for Treating STEMI Patients Michael O'Riordan August 27, 2017
News Conference News ESC 2017 CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events Michael O'Riordan August 27, 2017
News Daily News Evolocumab Not Cost-Effective at Current List Price Michael O'Riordan August 23, 2017
News Opinion Editor's Corner ESC 2017 ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On Shelley Wood August 18, 2017
News Daily News Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness Michael O'Riordan August 08, 2017
News Daily News ‘Remnant’ Cholesterol Linked With CVD Risk, Even When LDL Levels Are Low Michael O'Riordan August 01, 2017
News Daily News Staying on Statins After an Adverse Event Lowers Risks of Death, MI or Stroke Michael O'Riordan July 25, 2017
News Daily News Top-Line REVEAL Results Support Efficacy of CETP Inhibition, but Questions Abound Todd Neale June 27, 2017
News Features How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts Michael O'Riordan May 23, 2017
News Daily News $2 Billion Annual Price Tag for FOURIER-Eligible VA Patients on PCSK9 Inhibitor Michael O'Riordan May 12, 2017
News Daily News Long-term MI Risk Among Stable CAD Patients: Some Clues From CORONOR Shelley Wood April 24, 2017
News Daily News ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events Michael O'Riordan April 04, 2017
News Conference News ACC 2017 FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo Michael O'Riordan March 17, 2017